Download (4Mb) - Etheses - Saurashtra University

Part-1Review on Antiulcer Literatureof availability of more effective anti-secretory medications. A new era in the treatment ofacid-peptic disorders dawned with the launch of H2-receptor antagonist, cimetidine, in1976. This class of drugs, however, has a short duration of action. Peptic ulcers caused byH. pylori can be treated by combination of antibiotics and anti-secretory medications.However, complex drug regimen and associated side effects may limit usefulness. Launchof omeprazole in 1988 introduced a conceptually new approach of inhibition of protonpump in the management of acid-related disorders. PPI’s proved to be superior to any ofthe previously used drugs including H 2 -antagonists. Today, almost two decades afterintroduction of the first PPI, the apparent drawbacks of irreversible proton pumpinhibitors, mainly because of their prolonged acid suppression, are becoming a cause ofconcern. Hence, the researchers worldwide have been attracted toward designingreversible, shorter, and rapid acting acid pump antagonists (APAs). Thus, APAs are theconceivable future drugs for the treatment of acid-peptic disorders.48